Ucb ADR (UCBJY)

$42.80 0.11 (0.26%)

10:54 EDT UCBJY Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 16,622

Day's Range $42.45 - $42.82

52-Week Range $40.80 - $63.94

Dividend & Yield N/A (N/A)

UCBJY Stock Predictions, Articles, and Ucb ADR News

From the Web

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

From Benzinga May 30, 2022

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval

From Benzinga Mar 28, 2022

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

From Benzinga Feb 8, 2022

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More

From Talk Markets Jan 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More

From Benzinga Jan 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study

From Benzinga Jan 21, 2022

UCB SA (OTC: UCBJF) posted topline results from the Phase 3 BE COMPLETE study evaluating Bimzelx (bimekizumab) for active psoriatic arthritis patients who were...